Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 15.6% in January

Arvinas, Inc. (NASDAQ:ARVN) saw a large decrease in short interest in January. As of January 30th, there was short interest totaling 4,262,275 shares, a decrease of 15.6% from the January 15th total of 5,052,067 shares. Based on an average daily trading volume, of 720,790 shares, the short-interest ratio is presently 5.9 days. Currently, 7.0% of the company’s stock are sold short. Currently, 7.0% of the company’s stock are sold short. Based on an average daily trading volume, of 720,790 shares, the short-interest ratio is presently 5.9 days.

Arvinas Stock Performance

NASDAQ:ARVN opened at $11.44 on Wednesday. The firm’s fifty day moving average is $12.40 and its two-hundred day moving average is $10.32. The firm has a market cap of $734.68 million, a price-to-earnings ratio of -14.12 and a beta of 1.88. Arvinas has a one year low of $5.90 and a one year high of $20.38.

Analyst Ratings Changes

Several equities analysts recently commented on ARVN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research report on Monday, December 22nd. Citigroup raised shares of Arvinas from a “neutral” rating to a “buy” rating and raised their price target for the stock from $10.00 to $15.00 in a report on Tuesday, January 6th. Wedbush reissued a “neutral” rating and set a $9.00 price objective on shares of Arvinas in a report on Thursday, November 6th. Wall Street Zen downgraded Arvinas from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Wells Fargo & Company lowered their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Ten analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Arvinas currently has a consensus rating of “Hold” and a consensus target price of $13.12.

Hedge Funds Weigh In On Arvinas

Several institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its holdings in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after buying an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the period. State of Wyoming purchased a new stake in shares of Arvinas during the 3rd quarter worth about $68,000. Abel Hall LLC acquired a new stake in shares of Arvinas during the 4th quarter valued at about $125,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in shares of Arvinas in the 3rd quarter valued at about $92,000. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.